The pivotal role of hepatocytes in drug discovery

Chemico-Biological Interactions

Volumn 168, Issue 1, 2007, Pages 2-15

  Soars, Matthew G ^a   McGinnity, Dermot F ^a   Grime, Ken ^a   Riley, Robert J ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Clearance; Drug drug interaction (DDI); Hepatocytes; In vitro in vivo extrapolation (IVIVE)

Indexed keywords

CYTOCHROME P450;

CHRONOTHERAPY; DRUG ANTAGONISM; DRUG BINDING; DRUG CLEARANCE; DRUG DISPOSITION; DRUG INHIBITION; DRUG METABOLISM; DRUG RESEARCH; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; IN VITRO STUDY; ISOLATED LIVER; LIVER CELL; LIVER METABOLISM; LIVER MICROSOME; LIVER SLICE; METABOLIC CLEARANCE RATE; NONHUMAN; PROTEIN TRANSPORT; REVIEW;

ANIMALS; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; DRUG INTERACTIONS; HEPATOCYTES; HUMANS; METABOLIC CLEARANCE RATE; METABOLIC NETWORKS AND PATHWAYS; PHARMACEUTICAL PREPARATIONS;

EID: 34247492532     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2006.11.002     Document Type: Review

References (121)

1. Weibel E.R., Stäubli W., Gnägi H.R., and Hess F.A. Correlated morphometric and biochemical studies on the liver cell. I. Morphometric model, stereologic methods, and normal morphometric data for rat liver. J. Cell Biol. 42 (1969) 68-71
2. Prentis R.A., Lis Y., and Walker S.R. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br. J. Clin. Pharmacol. 25 (1988) 387-396
3. Riley R.J., and Grime K. Metabolic screening in vitro: metabolic stability, CYP inhibition and induction. Drug Discov. Today: Technol. 1 (2004) 365-372
4. Van de Waterbeemd H., and Gifford E. ADMET in silico modelling: towards prediction paradise?. Nat. Rev. Drug Discov. 2 (2003) 192-204
5. Kennedy T. Managing the drug discovery/development interface. Drug Discov. Today 2 (1997) 436-444
6. Reddy A., Heimbach T., Freiwald S., Smith D., Winters R., Michael S., Surendran N., and Cai H. Validation of a semi-automated human hepatocyte assay for the determination and prediction of intrinsic clearance in discovery. J. Pharm. Biomed. Anal. 37 (2005) 319-326
7. Jenkins K.M., Angeles R., Quintos M.T., Xu R., Kassel D.B., and Rourick R.A. Automated high throughput ADME assays for metabolic stability and cytochrome P450 inhibition profiling of combinatorial libraries. J. Pharm. Biomed. Anal. 34 (2004) 989-1004
8. Weaver R., Graham K.S., Beattie I.G., and Riley R.J. Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation. Drug Metab. Dispos. 31 (2003) 955-966
9. McGinnity D.F., Tucker J., Trigg S., and Riley R.J. Prediction of CYP2C9 mediated drug-drug interactions: a comparison using data from recombinant enzymes and human hepatocytes. Drug Metab. Dispos. 33 (2005) 1700-1707
10. Atkinson A., Kenny J.R., and Grime K. Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. Drug Metab. Dispos. 33 (2005) 1637-1647
11. Lim H.-K., Duczak N., Brougham L., Elliot M., Patel K., and Chan K. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes. Drug Metab. Dispos. 33 (2005) 1211-1219
12. McGinnity D.F., Parker A.J., Soars M.G., and Riley R.J. Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. Drug Metab. Dispos. 28 (2000) 1327-1334
13. Li A.P., Lu C., Brent J.A., Pham C., Fackett A., Ruegg C.E., and Silber P.M. Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem. Biol. Interact. 121 (1999) 17-35
14. Houston J.B., and Carlile D.J. Prediction of hepatic clearance from microsomes, hepatocytes and liver slices. Drug Metab. Rev. 29 (1997) 891-922
15. Grime K., and Riley R.J. The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions. Curr. Drug Metab. 7 (2006) 251-264
16. Obach R.S., Baxter J.G., Liston T.E., Silber B.M., Jones B.C., MacIntyre F., Rance D.J., and Wastall P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharm. Exp. Ther. 283 (1997) 46-58
17. Clarke S.E., and Jeffrey P. Utility of metabolic stability screening: comparison of in vitro and in vivo clearance. Xenobiotica 31 (2001) 591-598
18. Ayrton A., and Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31 (2001) 469-497
19. Griffin S.J., and Houston J.B. Comparison of fresh and cryopreserved rat hepatocyte suspensions for the prediction of in vitro intrinsic clearance. Drug Metab. Dispos. 32 (2004) 552-558
20. Tucker G.T., Houston J.B., and Huang S.-M. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-towards a consensus. Clin. Pharmacol. Ther. 70 (2001) 103-114
21. Shitara Y., Horie T., and Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur. J. Pharamaceut. Sci. 27 (2006) 425-446
22. Mizuno N., Niwa T., Yotsumoto Y., and Sugiyama Y. Impact of drug transporter studies on drug discovery and drug development. Pharmacol. Rev. 55 (2003) 425-461
23. Olinga P., Merema M., Hof I.H., Slooff M.J.H., Proost J.H., Meijer D.K.F., and Groothuis G.M.M. Characterization of the uptake of rocuronium and digoxin in human hepatocytes: carrier specificity and comparison with in vivo data. J. Pharamcol. Exp. Ther. 285 (1998) 506-510
24. Meier P.J., Eckhardt U., Schroeder A., Hagenbuch B., and Stieger B. Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology 26 (1997) 1667-1677
25. Riley R.J., Martin I.J., and Cooper A.E. The influence of DMPK as an integrated partner in modern drug discovery. Curr. Drug Metab. 3 2002 (2002) 527-550
26. Houston J.B. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47 (1994) 1469-1479
27. Roland M., Benet L.Z., and Graham G.G. Clearance concepts in pharmacokinetics. J. Pharmacokinet. Biopharm. 1 (1973) 123-136
28. Wilkinson G.R., and Shand D.G. Commentary: a physiological approach to hepatic drug clearance. Clin. Pharmacol. Ther. 18 (1975) 377-390
29. Pang K.S., and Roland M. Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocelluar enzyme activity on hepatic drug clearance. J. Pharmacokinet. Biopharm. 5 (1977) 625-653
30. Roberts M.S., and Roland M. Hepatic elimination-dispersion model. J. Pharm. Sci. 74 (1985) 585-587
31. Ito K., and Houston J.B. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm. Res. 21 (2004) 785-792
32. Iwatsubo T., Hirota N., Ooie T., Suzuki H., and Sugiyama Y. Prediction of in vivo drug disposition from in vivo data based on physiological pharmacokinetics. Biopharm. Drug Dispos. 17 (1996) 273-310
33. Ito K., Iwatsubo T., Kanamitsu S., Nakajima Y., and Sugiyama Y. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu. Rev. Pharmacol. Toxicol. 38 (1998) 461-499
34. Niro R., Byers J.P., Fournier R.L., and Bachmann K. Application of a convective-dispersion model to predict in vivo hepatic clearance from in vitro measurement utilizing cryopreserved human hepatocyes. Curr. Drug Metab. 4 (2003) 357-369
35. Rawden H.C., Carilie D.J., Tindall A., Hallifax D., Galetin A., Ito K., and Houston J.B. Microsomal prediction on in vivo clearance and associated interindividual variability of six benzodiazepines in humans. Xenobiotica 35 (2005) 603-625
36. Lin J.H. Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab. Dispos. 26 (1998) 1202-1212
37. Iwatsubo T., Hirota N., Ooie T., Suzuki H., Shimada N., Chiba K., Ishizaki T., Green C.E., Tyson C.A., and Sugiyama Y. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther. 73 (1997) 5147-5171
38. Carlile D.J., Hakooz N., Bayliss M.K., and Houston J.B. Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. Br. J. Clin. Pharmacol. 47 (1999) 625-635
39. Riley R.J., McGinnity D.F., and Austin R.P. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab. Dispos. 33 (2005) 1304-1311
40. Obach R.S. The importance of non-specific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations. Drug Metab. Dispos. 24 (1996) 1047-1049
41. Obach R.S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data. An examination of in vitro half-live approach and nonspecific binding to microsomes. Drug Metab. Dispos. 27 (1999) 1350-1359
42. Ito K., and Houston J.B. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm. Res. 22 (2005) 103-112
43. Miners J.O., Knights K.M., Houston J.B., and Mackenzie P.I. In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem. Pharmacol. 71 (2006) 1531-1539
44. Gillette J.R., and Pang K.S. Theoretical aspects of pharmacokinetic drug interactions. Clin. Pharmacol. Ther. 22 (1977) 623-639
45. Tang C., Lin Y., Rodrigues A.D., and Lin J.H. Effect of albumin on phenytoin and tolbutamide metabolism in human liver microsomes: an impact more than protein binding. Drug Metab. Dispos. 30 (2002) 648-654
46. Baba T., Touchi A., Ito K., Yamaguchi Y., Yamazoe Y., Ohno Y., and Sugiyama Y. Effects of serum albumin and liver cytocol on CYP2C9- and CYP3A4-mediated drug metabolism. Drug Metab. Pharmacokin. 17 (2002) 522-531
47. Bachmann K., Byers J., and Ghosh R. Prediction of in vivo hepatic clearance from in vitro data using cryopreserved human hepatocytes. Xenobiotia 33 (2003) 475-483
48. Roland Yeo K., Howgate E.M., Tucker G.T., and Rostami-Hodjegan A. Predicting the clearance of CYP2C9 substrates. Drug Metab. Dispos. 32 (2004) 1522
49. Naritomi Y., Terashita S., Kagayama A., and Sugiyama Y. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab. Dispos. 29 (2001) 1316-1324
50. McGinnity D.F., Soars M.G., Urbanowicz R.A., and Riley R.J. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab. Dispos. 32 (2004) 1247-1253
51. Mistry M., and Houston J.B. Glucuronidation in vitro and in vivo: comparison of intestinal and hepatic conjugation of morphine, naloxone and buprenorphine. Drug Metab. Dispos. 15 (1987) 710-717
52. Soars M.G., Burchell B., and Riley R.J. In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J. Pharmacol. Exp. Ther. 301 (2002) 382-390
53. Boase S., and Miners J.O. In vitro-in vivo correlations for drugs eliminated by glucuronidation: Investigations with the model substrate zidovudine. Br. J. Clin. Pharmacol. 54 (2002) 493-503
54. Rowland A., Elliott D.J., Williams A.J., Mackenzie P.I., Dickinson R.G., and Miners J.O. In vitro characterization of lamotrigine N2-glucurondation and the lamotrigine-valproic acid interaction. Drug Metab. Dispos. 34 (2006) 1055-1062
55. Uchaipichat V., Winner L.K., Mackenzie P.I., Elliot D.J., Williams J.A., and Miners J.O. Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br. J. Clin. Pharmacol. 61 (2006) 427-439
56. Soars M.G., Ring B.J., and Wrighton S.A. The effect of incubation conditions on the enzyme kinetics of UDP-glucuronosyltransferases. Drug Metab. Dispos. 31 (2003) 762-767
57. Hagenbuch B., and Meier P.J. The superfamily of organic anion transporting polypeptides. Biochim. Biophys. Acta 1609 (2003) 1-16
58. Hagenbuch B., and Meier P.J. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 447 (2004) 653-665
59. Burckhardt G., and Wolff N.A. Structure or renal organic anion and cation transporters. Am. J. Physiol. Renal Physiol. 278 (2000) F853-F866
60. Hagenbuch B., Scharschmidt B.F., and Meier P.J. Effect of antisense oligonucleotides on the expression of hepatocellular bile acid and organic anion uptake systems in Xenopus laevis oocytes. Biochem. J. 316 (1996) 901-904
61. Kullak-Ublick G.A., Ismair M.G., Stieger B., Landmann L., Huber R., Pizzaagalli F., Fattinger K., Meier P.J., and Hagenbuch B. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120 (2001) 525-533
62. Ismair M.G., Stieger B., Cattori V., Hagenbuch B., Fried M., Meier P.J., and Kullak-Ublick G.A. Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver. Gastroenterology 121 (2001) 1185-1190
63. Cui Y., König J., Leier I., Buchholz U., and Keppler D. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC1A6. J. Biol. Chem. 276 (2001) 9626-9630
64. Hirano M., Maeda K., Shitara Y., and Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J. Pharmacol. Exp. Ther. 311 (2004) 139-146
65. Shimizu M., Fuse K., Okudaira K., Nishigaki R., Maeda K., Kusuhara H., and Sugiyama Y. Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab. Dispos. 33 (2005) 1477-1481
66. Sasaki M., Suzuki H., Ito K., Abe T., and Sugiyama Y. Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and multidrug resistance-associated protein 2 (MRP2/ABCC2). J. Biol. Chem. 277 (2002) 6497-6503
67. Spears K.J., Ross J., Stenhouse A., Ward C.J., Goh L.-B., Wolf C.R., Morgan P., Ayrton A., and Friedburg T.H. Directional trans-epithelial transport of organic anions in orcine LLC-PK1 cells that co-express human OATP1B1 (OATP-C) and MRP2. Biochem. Pharmacol. 69 (2005) 415-423
68. Cui Y., König J., and Keppler D. Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Mol. Pharmacol. 60 (2001) 934-943
69. Letschert K., Komatsu M., Hummel-Eisenbeiss J., and Keppler D. Vectorial transport of the peptide CCK-8 by double-transfected MDCKII cells stably expressing the organic anion transporter OATP1B3 (OATP8) and the export pump ABCC2. J. Pharmacol. Exp. Ther. 313 (2005) 549-556
70. Kopplow K., Letschert K., König J., Walter B., and Keppler D. Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol. Pharmacol. 68 (2005) 1031-1038
71. Ghibellini G., Leslie E.K., and Brouwer K.L.R. Methods to evaluate biliary excretion of drugs in humans: an updated review. Mol. Pharm. 3 (2006) 198-211
72. Sasaki M., Suzuki H., Aoki J., Ito K., Meier P.J., and Sugiyama Y. Prediction of in vivo biliary clearance from the in vitro transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II monolayer expressing both rat organic anion transporting polypeptide 4 and multidrug resistance associated protein 2. Mol. Pharmacol. 66 (2004) 450-459
73. Kouzuki H., Suzuki H., Ito K., Ohashi R., and Sugiyama Y. Contribution of sodium taurocholate co-transporting polypeptide to the uptake of its possible substrates into rat hepatocytes. J. Pharmacol. Exp. Ther. 286 (1998) 1043-1050
74. Ishizuka H., Konno K., Naganuma H., Nishimura K., Kouzuki H., Suzuki H., Stieger B., Meier P.J., and Sugiyama Y. Transport of temocaprilat into rat hepatocytes: Role of organic anion transporting polypeptide. J. Pharmacol. Exp. Ther. 287 (1998) 37-42
75. Shitara Y., Li A.P., Kato Y., Lu C., Ito K., Itoh T., and Sugiyama Y. Function of uptake transporters for taurocholate and estradiol-17β-d-glucuronide in cryopreserved human hepatocytes. Drug Metab. Pharmacokin. 18 (2003) 33-41
76. Yamashiro W., Maeda K., Hirouchi M., Adachi Y., Hu Z., and Sugiyama Y. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab. Dispos. 34 (2006) 1247-1254
77. Crespi C.L. Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Adv. Drug Res. 26 (1995) 179-235
78. Nakajima M., Nakamura S., Tokudome S., Shimada N., Yamazaki H., and Yokoi T. Azelastine N-demethylation by cytochrome P-450 (CYP) 3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab. Dispos. 27 (1999) 1381-1391
79. Soars M.G., Gelboin H.V., Krausz K.W., and Riley R.J. A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology. Br. J. Clin. Pharmacol. 55 (2002) 175-181
80. Hasegawa M., Kusuhara H., Endou H., and Sugiyama Y. Contribution of organic anion transporters to the renal uptake of anionic compounds and nucleoside derivatives in rat. J. Pharmacol. Exp. Ther. 305 (2003) 1087-1097
81. Shitara Y., Sugiyama D., Kusuhara H., Kato Y., Abe T., Meier P.J., Itoh T., and Sugiyama Y. Comparative inhibitory effects of different compounds on rat oatp1 (sl21a1) and oatp2 (sl21a5)-mediated transport. Pharm. Res. 19 (2002) 147-153
82. Shitara Y., Itoh T., Sato H., Li A.P., and Sugiyama Y. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J. Pharmacol. Exp. Ther. 204 (2003) 610-616
83. Shitara Y., Hirano M., Sato H., and Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: Analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther. 311 (2004) 228-236
84. Tirona R.G., Leake B.F., Merino G., and Kim R.B. Polymorphisms in OATP-C. Identification of multiple allelic variants associated with altered transport activity among European and African-Americans. J. Biol. Chem. 276 (2001) 35669-35675
85. Michalski C., Cui Y., Nies A.T., Nuessler A.K., Neuhaus P., Zanger U.M., Klein K., Eichelbaum M., Keppler D., and König J. A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J. Biol. Chem. 277 (2002) 43058-43063
86. Nozawa T., Nakajima M., Tamai I., Noda K., Nezu J.-I., Sai Y., Tsuji A., and Yokoi T. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J. Pharmacol. Exp. Ther. 302 (2002) 804-813
87. Letschert K., Keppler D., and König J. Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics 14 (2004) 441-452
88. Nishizato Y., Ieiri I., Suzuki H., Kimura M., Kawabata K., Hirota T., Takane H., Irie S., Kusuhara H., Urasaki Y., Urae A., Higuchi S., Otsubo K., and Sugiyama Y. Polymorphisms of OATP-C (SL21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. 73 (2003) 554-565
89. Bertz R.J., and Granneman G.R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 32 (1997) 210-258
90. Fuhr U. Induction of drug metabolising enzymes: pharmacokinetic and toxicological consequences in humans. Clin. Pharmacokinet. 38 (2000) 493-504
91. Zhou S., Yung C.S., Cher G.B., Chan E., Duan W., Huang M., and McLeod H.L. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet. 44 (2005) 279-304
92. Cohen L.H., van Leeuwen R.E., van Thiel G.C., van Pelt J.F., and Yap S.H. Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm. Drug Dispos. 21 (2000) 353-364
93. Oleson F.B., Berman C.L., and Li A.P. An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes. Chem. Biol. Interact. 150 (2004) 137-147
94. Zhao P., Kunze K.L., and Lee C.A. Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes. Drug Metab. Dispos. 33 (2005) 853-861
95. Ring B.J., Patterson B.E., Mitchell M.I., Vandenbranden M., Gillespie J., Bedding A.W., Jewell H., Payne C.D., Forgue S.T., Eckstein J., Wrighton S.A., and Phillips D.L. Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo. Clin. Pharmacol. Ther. 77 (2005) 63-75
96. McGinnity D.F., Berry A.J., Kenny J.R., Grime K., and Riley R.J. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. Drug Metab. Dispos. 34 (2006) 1291-1300
97. Di Marco A., Yao D., and Laufer R. Demethylation of radiolabelled dextromethorphan in rat microsomes and intact hepatocytes. Eur. J. Biochem. 270 (2003) 3768-3777
98. Yao C., Kunze K.L., Kharasch E.D., Wang Y., Trager W.F., Ragueneau I., and Levy R.H. Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. Clin. Pharmacol. Ther. 70 (2001) 415-424
99. Yao C., Kunze K.L., Trager W.F., Kharasch E.D., and Levy R.H. Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19. Drug Metab. Dispos. 31 (2003) 565-571
100. Ito K., Hallifax D., Obach R.S., and Houston J.B. Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab. Dispos. 33 (2005) 837-844
101. Williams J.A., Hyland R., Jones B.C., Smith D.A., Hurst S., Goosen T.C., Peterkin V., Koup J.R., and Ball S.E. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab. Dispos. 32 (2004) 1201-1208
102. Lim H.K., Duczak Jr. N., Brougham L., Elliot M., Patel K., and Chan K. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes. Drug Metab. Dispos. 33 (2005) 1211-1219
103. Ito K., Ogihara K., Kanamitsu S.I., and Itoh T. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab. Dispos. 31 (2003) 945-954
104. Mayhew B.S., Jones D.R., and Hall S.D. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab. Dispos. 28 (2000) 1031-1037
105. Bertelsen K.M., Venkatakrishnan K., von Moltke L.L., Obach R.S., and Greenblatt D.J. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab. Dispos. 31 (2003) 289-293
106. Kobayashi K., Yamamoto T., Chiba K., Tani M., Ishizaki T., and Kuroiwa Y. The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4′-hydroxylase activity in human liver microsomes. Br. J. Clin. Pharmacol. 40 (1995) 481-485
107. Lopez-Garcia M.P., Dansette P.M., and Mansuy D. Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: inactivation of yeast-expressing human liver cytochrome P-450 2C9 by tienilic acid. Biochemistry 33 (1994) 166-175
108. Chan W.K., Delucchi A.B., and Resveratrol. a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci. 67 (2000) 3103-3112
109. Kanamitsu S., Ito K., Green C.E., Tyson C.A., Shimada N., and Sugiyama Y. Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm. Res. 17 (2000) 419-426
110. Yamano K., Yamamoto K., Katashima M., Kotaki H., Takedomi S., Matsuo H., Ohtani H., Sawada Y., and Iga T. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. Drug Metab. Dispos. 29 (2001) 443-452
111. Dai R., Wei X., Luo G., Sinz M., and Marathe P. Metabolism-dependent P450 3A4 inactivation with multiple substrates. Abstract from 12th North American ISSX Meeting. Providence, RI. Drug Metab. Rev. 35 (2003) 341
112. McConn D.J., Lin Y.S., Allen K., Kunze K.L., and Thummel K.E. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. Drug Metab. Dispos. 32 (2004) 1083-1091
113. Riley R.J. The potential pharmacological and toxicological impact of P450 screening. Curr. Opin. Drug Discov. Devel. 4 (2001) 45-54
114. Lu C., and Li A.P. Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog. Chem. Biol. Interact. 134 (2001) 271-281
115. Riley R.J., and Kenna J.G. Cellular models for ADMET predictions and evaluation of drug-drug interactions. Curr. Opin. Drug Discov. Dev. 7 (2004) 86-99
116. LeCluyse E., Madan A., Hamilton G., Carroll K., DeHaan R., and Parkinson A. Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes. J. Biochem. Mol. Toxicol. 14 (2000) 177-188
117. Kato M., Chiba K., Horikawa M., and Sugiyama Y. The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes. Drug Metab. Pharmacokinet. 20 (2005) 236-243
118. Luo G., Guenthner T., Gan L.S., and Humphreys W.G. CYP3A4 induction by xenobiotics: biochemistry, experimental methods and impact on drug discovery and development. Curr. Drug Metab. 5 (2004) 483-505
119. Soars M.G., Petullo D.M., Eckstein J.A., Kasper S.C., and Wrighton S.A. An assessment of UDP-glucuronosyltransferase induction using primary human hepatocytes. Drug Metab. Dispos. 32 (2004) 140-148
120. Pichard L., Fabre I., Fabre G., Domergue J., Saint Aubert B., Mourad G., Maurel P., and Cyclosporin. A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporine A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab. Dispos. 18 (1990) 595-606
121. Ripp S.L., Mills J.B., Fahmi O.A., Trevena K.A., Liras J.L., Maurer T.S., and de Morais S.M. Use of immortalized human heptocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug Metab. Dispos. 34 (2006) 1742-1748